Donate

Quantitative Imaging Workshop

Quantitative Imaging Workshop XVII: Leveraging CT to Accelerate Detection of Lung Cancer, COPD and Cardiovascular Disease

Quantitative Imaging Workshop XVII: Leveraging CT to Accelerate Detection of Lung Cancer, COPD and Cardiovascular Disease

October 28-30, 2020 | Virtual

For 17 years, the Prevent Cancer Foundation has believed in the importance of advancing the field of quantitative CT imaging to detect and manage early thoracic disease. To demonstrate our commitment to making this Workshop as widely available as possible, the Foundation, in partnership with the American Lung Association and the Workshop sponsors (the American Cancer Society/ National Lung Cancer Roundtable, Early Diagnosis and Treatment Research Foundation on behalf of the Initiative for Early Lung Cancer Research on Treatment (IELCART), AstraZeneca, Genentech, Helsinn and GO2 Foundation) are making the Workshop available without charge to anyone who would like to register.

Agenda

QIW XVII Outreach One-Pager

Quantitative Imaging Workshop XVII is a high-impact multi-disciplinary forum for the advancement of quantitative low-dose computerized tomography (LDCT) imaging biomarkers for detection and management of early thoracic disease—lung cancer, COPD and cardiovascular disease—three of the top four leading causes of death in the U.S. Now, amidst the COVID-19 pandemic, we approach this year’s Workshop with a sense of urgency.

Since 2004, the Prevent Cancer Foundation® has convened a series of annual Workshops to exchange ideas on exciting new biomedical opportunities that this transformational technology enables as well as information on the quality and consistency of policy and advocacy for responsible lung cancer, COPD and cardiovascular screening.

For the first time in 17 years, the Workshop will be held virtually, allowing for even greater global participation from oncologists, pulmonologists, surgeons, radiologists, cardiologists and imaging scientists, along with representatives of federal agencies, the pharmaceutical and imaging industries and patient advocates.

Rapid advances in medical imaging allow us to explore more accurate characterization of the clinical aggressiveness of early thoracic disease using computational analysis of high-quality thoracic CT images. This year’s Workshop will include:

  • A collaboration with the Quantitative Imaging Biomarkers Alliance – American Cancer Society/National Lung Cancer Roundtable to explore the implications of image quantitation as a clinical tool to measure changes in small suspected lung nodules in high-risk individuals.
  • International expert-led discussion on the potential benefits of quantitative imaging techniques in managing early lung cancer and other tobacco-related diseases.
  • Review of the accuracy/reliability of powerful new imaging tools as they are applied to early lung disease management.
  • A forum held in partnership with the American Lung Association and including leading thoracic imaging experts. The goal of this is to ensure CT screening scans can be reliably used for quantitative analyses for both lung cancer and COPD. It will examine clinical practice recommendations for the extent of COPD changes found with CT screening.
  • Distill clinical practice recommendations for the extent of COPD changes found with CT screening.
  • Multi-disciplinary exploration of therapeutic interventions to extend curative options beyond thoracic surgery for screen-detected early lung cancer. Session sponsored by the Early Diagnosis and Treatment Research Foundation on behalf of the Initiative for Early Lung Cancer Research on Treatment (IELCART).

Since 2004, the Quantitative Imaging Workshop focuses on the advancement of quantitative low-dose computerized tomography (LDCT) imaging biomarkers for detection and management of early thoracic disease—lung cancer, COPD and cardiovascular disease—three of the top four leading causes of death in the U.S.

Beginning in 2013, each year at the Workshop the Prevent Cancer Foundation® presents the James L. Mulshine, M.D., National Leadership Award to an individual who has had a profound impact on reducing the toll these diseases take on the health of Americans and individuals around the world.

Past recipients of this award include:

  • 2019 – Andrew C. von Eschenbach, M.D., Director, National Cancer Institute, for his design, implementation and management of the largest and most expensive clinical trial in its history, the National Lung Screening Trial (NLST)
  • 2018 – Sharon Y. Eubanks, U.S. Department of Justice, for her work as the lead Justice Department prosecutor in the landmark racketeering trial against Big Tobacco, a case which defied predictions and was won by the government
  • 2017 – The late John Walsh, President and CEO of the COPD Foundation and President and Founder of the Alpha One Foundation
  • 2016 – Laurie Fenton Ambrose, President and CEO of the Lung Cancer Alliance, for her efforts to guide patient advocacy groups in successful efforts to gain coverage of lung cancer screening by the Centers for Medicare & Medicaid Services (CMS)
  • 2015 – Claudia Henschke, Ph.D., M.D., Mt. Sinai Medical Center, as a pioneer of the use of low-dose spiral CT to screen for lung cancer
  • 2014 – CVS Health, award accepted by Nancy Gagliano, M.D., CVS Chief Medical Officer, in recognition of the company’s bold decision to discontinue the sale of tobacco products in their stores
  • 2013 (Inaugural year of the Award) – Cheryl G. Healton, Ph.D., President and CEO, Legacy Foundation and Dean of the College of Public Health at New York University, in recognition of over 25 years of tireless work in public health, specifically on tobacco control

Support the Quantitative Imaging Workshop  

The Prevent Cancer Foundation® values its partnerships with its supporters–and appreciates the impact we make together on increasing cancer screening. As a supporter of the 2020 Quantitative Imaging Workshop, you have a terrific opportunity to help advance work in cancer screening.

If your organization would like to support the Quantitative Imaging Workshop, or for more information on how you can become a corporate partner of the Prevent Cancer Foundation®, please contact Jennifer Niyangoda at 703-837-3684 or jennifer.niyangoda@preventcancer.org

If you personally would like to support the Foundation, please go to donate.

Special thanks to the 2020 Quantitative Imaging Workshop supporters!

 

American Lung Association

American Cancer Society

AstraZeneca

Genentech

Helsinn

GO2 Foundation

Join now to keep up with the latest in cancer prevention and early detection